Nonalcoholic Steatohepatitis (NASH) is a silent progressive liver disease that needs attention. Due to its lack of symptoms, NASH is often unrecognized and under diagnosed.  The highest prevalence of NASH is in those who are obese and/or have type 2 diabetes, hypertension and other cardiovascular disease.  Patients with NASH can develop fibrosis and ultimately cirrhosis of the liver potentially leading to liver cancer or requiring a liver transplant. 

Currently there is no approved medication to treat NASH.

If you have been diagnosed with NASH, you may be eligible to participate in a landmark study investigating a medication that could potentially reduce the steatosis or excessive fat from the liver.

To qualify you must:

• Be between ages 18-70
• Have type 2 diabetes (HbA1c 7 - 10.5)
• Be taking metformin only for diabetes
• Have liver fat >/=8% by MRI-PDFF

Qualified participants will  receive:

• Investigational study medication and study-related medical care at no cost
• Reimbursement for time and travel 

Health Insurance is not required to participate.

Call 416--844-2990 or complete the short form.